Beta Bionics (BBNX) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Beta Bionics

NasdaqGM•Healthcare•Medical Devices

$17.58-0.27(-0.02%)Pre-market

Market Cap

$702.78M

P/S

5.5x

P/B

1.8x

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Profitability (15/25); weakest: Cash & Earnings Quality (8/25).

Profitability15/25

Growth11/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 5.5x5y range 4.0x – 14.2x

Currently near its 5-quarter median.

P/B · 1.8x5y range 1.2x – 4.9x

Currently near its 7-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $702.78M

Metrics at a Glance

as of September 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $127.27M
Q. Revenue: $35.51M
TTM EBITDA: $-89.86M
TTM Op. Income: $-92.58M
Q. Op. Income: $-26.61M
TTM Net Income: $-83.12M
Q. Net Income: $-24.35M
EPS: $-0.52
Shares Out.: $46.54M

$127.27M in TTM revenue declined 4.5% YoY, reaching $35.51M last quarter. TTM EBITDA of $-89.86M and TTM operating income of $-92.58M show growth is flowing through to the bottom line. However, net income is negative at $83.12M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 3 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.3%
EBITDA Margin: -72.4%
Op. Margin: -74.9%
Net Margin: -68.6%

Op. margin of -74.9% is down 12.4% YoY — costs are rising relative to revenue. Net margin at -68.6% and gross margin of 57.3% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 5.5x
P/B Ratio: 1.8x

P/S of 5.5x and P/B of 1.8x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $443.76M
Cash: $81.55M
Long-Term Debt: N/A
Book Value: $401.38M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-12.29M
TTM Free Cash Flow: $-65.96M
FCF Margin: -51.8%
FCF / Net Income: 0.8

TTM FCF of $-65.96M on $-12.29M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 3 consecutive quarters — a weakening trend.